Q32 Bio Inc.
QTTBHealthcare|Biotechnology|US
$9.25
+0.40 (+4.52%)
DCF Value
$9.30
Tangible Book / Share
$12.55
Graham Number
$26.68
Cash / Share
$12.64
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05509023 Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) | Atopic Dermatitis | P2 | Active | 102 | RCT, Double-blind | ADX-914, Placebo |
| NCT06018428 A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) | Alopecia Areata | P2 | Active | 75 | Open-label | bempikibart (ADX-914) |
| NCT04485481 Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers | Safety Issues | P1 | Completed | 42 | RCT, Double-blind | ADX-914, Placebo, ADX-914, Placebo |